| EPLBA07 | Host genetic variants regulates CCR5 expression on immune cells: a study in people living with HIV and healthy controls | E-poster | Correlates of HIV susceptibility, and progression versus control (biomarkers and genetics) |
| EPLBA08 | ILC3s in HIV-infected lymph nodes up-regulate inflammatory pathways linked to tissue fibrosis | E-poster | Innate immunity (including NK cells) |
| EPLBB01 | Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomized controlled trial | E-poster | Tuberculosis: Prevention, diagnosis, treatment |
| EPLBB02 | Chronic/latent viral infection prevalence and estimated all-cause mortality risk among women living with HIV and HIV-negative women participating in the British Columbia CARMA-CHIWOS Collaboration (BCC3) study: preliminary findings | E-poster | Opportunistic infections (excluding TB): Bacterial, non-TB mycobacterial, viral and parasitic infections |
| EPLBB03 | Cervical cancer screening outcomes among women living with HIV In Malawi | E-poster | Other non-communicable diseases |
| EPLBB04 | Randomised study of switch toDTG/RPV in subjects with HIV RNA <50c/ml and archived K103N over 48 weeks | E-poster | Regimen simplification and switch studies |
| EPLBB05 | Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPLBB06 | Suboptimal lopinavir exposure in infants 1-12 months on rifampicin treatment receiving double-dosed or semi-superboosted lopinavir/ritonavir; results from the EMPIRICAL trial | E-poster | Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations |
| EPLBB07 | A point-of-care triage test for HIV virological failure: filling the gaps in viral load coverage | E-poster | Novel approaches to assess viral load and ARV resistance/tropism |
| EPLBB08 | Analytical treatment interruption (ATI) among African women with early ART initiation with or without VRC01 circulating at HIV acquisition: study design and early observations of viral rebound and control | E-poster | Cure interventions |